Novartis Pharma B.V.

Location

Noord-Holland

Founded

1948-02-10

Risk Signals

21161 news mentions monitored

Industry Context

This company is tracked across risk categories, including those related to its sector (e.g., Drugs, Drug Proprietaries, and Druggists' Sundries), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.

Recent Articles about Novartis Pharma B.V.

Live alerts from global media, monitored by Business Radar

MC Analysis I Why India’s cardiology pharma market is expecting a major disruption this year

2023-01-19 (moneycontrol.com)

MC Analysis I Why India’s cardiology pharma market is expecting a major disruption this year

With a blockbuster heart failure drug Vymada going off-patent this month, its much cheaper generic versions by a number of drug makers are set to hit the market in India and several other countries.

Read more
NICE's thumbs-up on Lilly's migraine med Emgality leaves rivals from Novartis and Teva in the dust

2020-11-18 (fiercepharma.com)

NICE's thumbs-up on Lilly's migraine med Emgality leaves rivals from Novartis and Teva in the dust

England's drug cost watchdogs have not been gentle on companies marketing hot but expensive new CGRP inhibitors to treat migraine headaches. | England 's National Institute of Health and Care Excellence recommended Eli Lilly 's CGRP inhibitor Emgality to treat migraines after limiting the use of

Read more
Amgen's Enbrel fends off biosimilar threat—and heads toward blockbuster superstardom

2020-07-02 (fiercepharma.com)

Amgen's Enbrel fends off biosimilar threat—and heads toward blockbuster superstardom

With Amgen’ s top line facing pressure for quite some time from biosimilar versions of flagship drugs like Epogen and Neulasta, the prospect that it could lose exclusivity on its top-selling product| The U.S. Federal Appeals Court upheld a 2019 ruling that kept Novartis’ biosimilar rival to Enbrel

Read more
Novartis' latest attempt to fend off MSN's Entresto generic falls short on appeal |

(fiercepharma.com)

Novartis' latest attempt to fend off MSN's Entresto generic falls short on appeal |

Novartis' latest effort to block a generic challenger to blockbuster heart med Entresto has come up short, this time in a federal appeals court. | The U.S. Court of Appeals for the Federal Circuit sided with a prior ruling that denied Novartis' motion seeking an injunction to prevent MSN's generic rival from launching.

Read more

Never miss a headline about Novartis Pharma B.V.

Set up smart alerts with Business Radar and receive real-time updates on any new risk signal or major news story.

  • ✔️ Used by 100+ compliance teams and analysts
  • ✔️ Covers 154M+ sources in 40+ languages